Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MediWound (MDWD) EBITDA (2016 - 2025)

MediWound has reported EBITDA over the past 13 years, most recently at -$7.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 84.04% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached $2.8 million, up 115.66%, while the annual FY2025 figure was -$23.9 million, 20.91% up from the prior year.
  • EBITDA for Q4 2025 was -$7.2 million at MediWound, down from -$2.7 million in the prior quarter.
  • Over five years, EBITDA peaked at $13.3 million in Q2 2025 and troughed at -$10.3 million in Q3 2024.
  • A 5-year average of -$2.7 million and a median of -$3.5 million in 2021 define the central range for EBITDA.
  • On a YoY basis, EBITDA climbed as much as 588.1% in 2024 and fell as far as 370.03% in 2024.
  • Year by year, EBITDA stood at -$4.2 million in 2021, then tumbled by 80.0% to -$7.5 million in 2022, then surged by 76.54% to -$1.8 million in 2023, then crashed by 122.58% to -$3.9 million in 2024, then tumbled by 84.04% to -$7.2 million in 2025.
  • Business Quant data shows EBITDA for MDWD at -$7.2 million in Q4 2025, -$2.7 million in Q3 2025, and $13.3 million in Q2 2025.